| Code | CSB-RA024404MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to ABBV-8736, designed for research targeting Triggering Receptor Expressed on Myeloid cells 1 (TREM1). TREM1 is a cell surface receptor predominantly expressed on neutrophils and monocytes that amplifies inflammatory responses through association with DAP12 signaling adaptor protein. Upon activation, TREM1 triggers the release of pro-inflammatory cytokines and chemokines, playing a critical role in innate immune responses. Dysregulated TREM1 signaling has been implicated in sepsis, acute respiratory distress syndrome, inflammatory bowel disease, and various autoimmune conditions. Elevated soluble TREM1 levels serve as biomarkers for infection severity and inflammatory disease progression.
ABBV-8736 represents a therapeutic antibody developed to modulate TREM1-mediated inflammatory pathways. This biosimilar provides researchers with a valuable tool for investigating TREM1 biology, exploring immune cell activation mechanisms, and evaluating potential therapeutic interventions in inflammation-driven pathologies. The antibody enables studies examining TREM1's role in pathogen recognition, inflammatory cascade regulation, and immune cell function across diverse disease models.
There are currently no reviews for this product.